{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:44:33Z","timestamp":1793295873089,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-018944"],"award-info":[{"award-number":["INV-018944"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["226137\/Z\/22\/Z"],"award-info":[{"award-number":["226137\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["6084COAP2020"],"award-info":[{"award-number":["6084COAP2020"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Omicron BA.2.86 subvariant differs from Omicron BA.2 as well as recently circulating variants by over 30 mutations in the spike protein alone. Here we report on the isolation of the live BA.2.86 subvariant from a diagnostic swab collected in South Africa which we tested for escape from neutralizing antibodies and viral replication properties in cell culture. We found that BA.2.86 does not have significantly more escape relative to Omicron XBB.1.5 from neutralizing immunity elicited by either Omicron XBB-family subvariant infection or from residual neutralizing immunity of recently collected sera from the South African population. BA.2.86 does have extensive escape relative to ancestral virus with the D614G substitution (B.1 lineage) when neutralized by sera from pre-Omicron vaccinated individuals and relative to Omicron BA.1 when neutralized by sera from Omicron BA.1 infected individuals. BA.2.86 and XBB.1.5 show similar viral infection dynamics in the VeroE6-TMPRSS2 and H1299-ACE2 cell lines. We also investigate the relationship of BA.2.86 to BA.2 sequences. The closest BA.2 sequences are BA.2 samples from Southern Africa circulating in early 2022. Similarly, many basal BA.2.86 sequences were sampled in Southern Africa. This suggests that BA.2.86 potentially evolved in this region, and that unobserved evolution led to escape from neutralizing antibodies similar in scale to recently circulating strains of SARS-CoV-2.<\/jats:p>","DOI":"10.1038\/s41467-023-43703-3","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T08:26:48Z","timestamp":1701851208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7565-7400","authenticated-orcid":false,"given":"Khadija","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gila","family":"Lustig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6138-6539","authenticated-orcid":false,"given":"Cornelius","family":"R\u00f6mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Reedoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zesuliwe","family":"Jule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farina","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashica","family":"Ganga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7498-2391","authenticated-orcid":false,"given":"Mallory","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurelle","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boitshoko","family":"Mahlangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1854-5573","authenticated-orcid":false,"given":"Anele","family":"Mnguni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayanda","family":"Nzimande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dikeledi","family":"Kekana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buhle","family":"Ntozini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"van Deventer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithendra","family":"Manickchund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-7489","authenticated-orcid":false,"given":"Bernadett I.","family":"Gosnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0926-710X","authenticated-orcid":false,"given":"Richard J.","family":"Lessells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0985-477X","authenticated-orcid":false,"given":"Quarraisha Abdool","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4986-2133","authenticated-orcid":false,"given":"Salim S.","family":"Abdool Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6191-4023","authenticated-orcid":false,"given":"Mahomed-Yunus S.","family":"Moosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3027-5254","authenticated-orcid":false,"given":"Tulio","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-7455","authenticated-orcid":false,"given":"Anne","family":"von Gottberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9526-0133","authenticated-orcid":false,"given":"Nicole","family":"Wolter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2525-1407","authenticated-orcid":false,"given":"Richard A.","family":"Neher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-2004","authenticated-orcid":false,"given":"Alex","family":"Sigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"43703_CR1","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cell.2023.02.001","volume":"186","author":"B Dadonaite","year":"2023","unstructured":"Dadonaite, B. et al. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike. Cell 186, 1263\u201378.e20 (2023).","journal-title":"Cell"},{"key":"43703_CR2","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2-preliminary report. N. Engl. J. Med. 383, 1920\u20131931 (2020).","journal-title":"N. Engl. J. Med."},{"key":"43703_CR3","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"C Keech","year":"2020","unstructured":"Keech, C. et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 383, 2320\u20132332 (2020).","journal-title":"N. Engl. J. Med."},{"key":"43703_CR4","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439\u20132450 (2020).","journal-title":"N. Engl. J. Med."},{"key":"43703_CR5","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"DY Logunov","year":"2020","unstructured":"Logunov, D. Y. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet 396, 887\u2013897 (2020).","journal-title":"Lancet"},{"key":"43703_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"43703_CR7","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N. Engl. J. Med. 384, 1824\u20131835 (2021).","journal-title":"N. Engl. J. Med."},{"key":"43703_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect. Dis. 21, 181\u2013192 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"43703_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella, R. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect. Dis. 21, 637\u2013646 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"43703_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21444-5","volume":"12","author":"AK Wheatley","year":"2021","unstructured":"Wheatley, A. K. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 12, 1162 (2021).","journal-title":"Nat. Commun."},{"key":"43703_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"43703_CR12","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"43703_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671\u2013681 (2021).","journal-title":"Lancet"},{"key":"43703_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"43703_CR15","doi-asserted-by":"crossref","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","DOI":"10.1038\/s41591-021-01377-8"},{"key":"43703_CR16","doi-asserted-by":"crossref","unstructured":"Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654\u2013656 (2022).","DOI":"10.1038\/s41586-021-04387-1"},{"key":"43703_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32396-9","volume":"13","author":"K Khan","year":"2022","unstructured":"Khan, K. et al. Omicron BA.4\/BA.5 escape neutralizing immunity elicited by BA.1 infection. Nat. Commun. 13, 4686 (2022).","journal-title":"Nat. Commun"},{"key":"43703_CR18","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","volume":"184","author":"M McCallum","year":"2021","unstructured":"McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184, 2332\u20132347.e16 (2021).","journal-title":"Cell"},{"key":"43703_CR19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682\u2013687 (2020).","journal-title":"Nature"},{"key":"43703_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37176-7","volume":"14","author":"D Cromer","year":"2023","unstructured":"Cromer, D. et al. Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. Nat. Commun. 14, 1633 (2023).","journal-title":"Nat. Commun."},{"key":"43703_CR21","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996\u20131012.e19 (2020).","journal-title":"Cell"},{"key":"43703_CR22","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861\u2013880 (2021).","journal-title":"Cell"},{"key":"43703_CR23","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e15 (2020).","journal-title":"Cell"},{"key":"43703_CR24","doi-asserted-by":"crossref","unstructured":"Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 603, 488\u2013492 (2022).","DOI":"10.1038\/s41586-022-04460-3"},{"key":"43703_CR25","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2022.03.022","volume":"185","author":"V Naranbhai","year":"2022","unstructured":"Naranbhai, V. et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell 185, 1259 (2022).","journal-title":"Cell"},{"key":"43703_CR26","doi-asserted-by":"crossref","unstructured":"Neher R. A. Contributions of adaptation and purifying selection to SARS-CoV-2 evolution. Virus Evol. 8, veac113 (2022).","DOI":"10.1093\/ve\/veac113"},{"key":"43703_CR27","doi-asserted-by":"publisher","first-page":"eabn4947","DOI":"10.1126\/science.abn4947","volume":"376","author":"JR Pulliam","year":"2022","unstructured":"Pulliam, J. R. et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science 376, eabn4947 (2022).","journal-title":"Science"},{"key":"43703_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41392-021-00604-5","volume":"6","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry. Signal. Transduct. Target Ther. 6, 189 (2021).","journal-title":"Signal. Transduct. Target Ther."},{"key":"43703_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11048-5","volume":"10","author":"T Reisl\u00e4nder","year":"2019","unstructured":"Reisl\u00e4nder, T. et al. BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nat Commun. 10, 3143 (2019).","journal-title":"Nat Commun."},{"key":"43703_CR30","doi-asserted-by":"publisher","first-page":"930086","DOI":"10.3389\/fimmu.2023.930086","volume":"14","author":"JKS Duncan","year":"2023","unstructured":"Duncan, J. K. S. et al. Interferon regulatory factor 3 mediates effective antiviral responses to human coronavirus 229E and OC43 infection. Front. Immunol. 14, 930086 (2023).","journal-title":"Front. Immunol."},{"key":"43703_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.omtn.2016.12.007","volume":"6","author":"M Machitani","year":"2017","unstructured":"Machitani, M. et al. Type I interferons impede short hairpin RNA-mediated RNAi via inhibition of dicer-mediated processing to small interfering RNA. Mol. Ther. Nucleic Acids 6, 173\u2013182 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"43703_CR32","doi-asserted-by":"publisher","first-page":"e1008690","DOI":"10.1371\/journal.ppat.1008690","volume":"17","author":"B Gao","year":"2021","unstructured":"Gao, B. et al. Inhibition of anti-viral stress granule formation by coronavirus endoribonuclease nsp15 ensures efficient virus replication. PLoS Pathog. 17, e1008690 (2021).","journal-title":"PLoS Pathog."},{"key":"43703_CR33","doi-asserted-by":"crossref","unstructured":"Uriu, K. et al. Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant. Lancet Infect. Dis. 23, e460\u2013e461 (2023).","DOI":"10.1016\/S1473-3099(23)00575-3"},{"key":"43703_CR34","doi-asserted-by":"crossref","unstructured":"Yang, S. et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect. Dis. 23, e457\u2013e459 (2023).","DOI":"10.1016\/S1473-3099(23)00573-X"},{"key":"43703_CR35","doi-asserted-by":"crossref","unstructured":"Sheward, D. J. et al. Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses. Lancet Infect. Dis. 23, e462\u2013e463 (2023).","DOI":"10.1016\/S1473-3099(23)00588-1"},{"key":"43703_CR36","doi-asserted-by":"publisher","unstructured":"Wang, Q. et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. bioRxiv https:\/\/doi.org\/10.1038\/s41586-023-06750-w (2023)","DOI":"10.1038\/s41586-023-06750-w"},{"key":"43703_CR37","doi-asserted-by":"publisher","unstructured":"Qu, P. et al. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 Omicron BA.2.86 and flip variants. bioRxiv https:\/\/doi.org\/10.1101\/2023.09.11.557206 (2023)","DOI":"10.1101\/2023.09.11.557206"},{"key":"43703_CR38","doi-asserted-by":"crossref","unstructured":"Lasrado, E. D. et al. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86. Vaccine 41, 6904\u20136909 (2023).","DOI":"10.1016\/j.vaccine.2023.10.051"},{"key":"43703_CR39","doi-asserted-by":"publisher","unstructured":"Lassauni\u00e8re, R. et al. Neutralisation of SARS-CoV-2 Omicron subvariants BA.2.86 and EG.5.1 by antibodies induced by earlier infection or vaccination. bioRxiv https:\/\/doi.org\/10.1101\/2023.10.01.560365 (2023).","DOI":"10.1101\/2023.10.01.560365"},{"key":"43703_CR40","doi-asserted-by":"crossref","unstructured":"Hu, Y. et al. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1. Emerg. Microbes Infect. 12, 2271089 (2023).","DOI":"10.1080\/22221751.2023.2271089"},{"key":"43703_CR41","doi-asserted-by":"crossref","unstructured":"Karim, F. et al. HIV status alters disease severity and immune cell responses in beta variant SARS-CoV-2 infection wave. Elife 10, e67397 (2021).","DOI":"10.1101\/2020.11.23.20236828"},{"key":"43703_CR42","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1016\/S2352-3018(18)30104-8","volume":"5","author":"ABM Kharsany","year":"2018","unstructured":"Kharsany, A. B. M. et al. Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey. Lancet HIV. 5, e427\u2013e437 (2018).","journal-title":"Lancet HIV."},{"key":"43703_CR43","doi-asserted-by":"crossref","unstructured":"Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature 603, 706\u2013714 (2022).","DOI":"10.1038\/s41586-022-04474-x"},{"key":"43703_CR44","doi-asserted-by":"publisher","unstructured":"Karim, F. et al. Emergence of neutralizing antibodies associates with clearance of SARS-CoV-2 during HIV-mediated immunosuppression. medRxiv https:\/\/doi.org\/10.1101\/2023.08.18.23293746 (2023).","DOI":"10.1101\/2023.08.18.23293746"},{"key":"43703_CR45","doi-asserted-by":"crossref","unstructured":"Cele, S. et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe 30, 154\u2013162.e5 (2022).","DOI":"10.1016\/j.chom.2022.01.005"},{"key":"43703_CR46","doi-asserted-by":"crossref","unstructured":"Peacock, T. P., Penrice-Randal, R., Hiscox, J. A. & Barclay W. S. SARS-CoV-2 one year on: evidence for ongoing viral adaptation. J. Gen. Virol. 102, 001584 (2021).","DOI":"10.1099\/jgv.0.001584"},{"key":"43703_CR47","doi-asserted-by":"publisher","first-page":"109017","DOI":"10.1016\/j.celrep.2021.109017","volume":"35","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Rep. 35, 109017 (2021).","journal-title":"Cell Rep."},{"key":"43703_CR48","doi-asserted-by":"crossref","unstructured":"Shu, Y. & McCauley, J. GISAID: global initiative on sharing all influenza data-from vision to reality. Euro Surveill. 22, 30494 (2017).","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494"},{"key":"43703_CR49","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.21105\/joss.03773","volume":"6","author":"I Aksamentov","year":"2021","unstructured":"Aksamentov, I., Roemer, C., Hodcroft, E. B. & Neher, R. A. Nextclade: clade assignment, mutation calling and quality control for viral genomes. J. Open Source Software. 6, 3773 (2021).","journal-title":"J. Open Source Software."},{"key":"43703_CR50","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/molbev\/msaa015","volume":"37","author":"BQ Minh","year":"2020","unstructured":"Minh, B. Q. et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol. Biol. Evol. 37, 1530\u20131534 (2020).","journal-title":"Mol. Biol. Evol."},{"key":"43703_CR51","doi-asserted-by":"publisher","first-page":"vex042","DOI":"10.1093\/ve\/vex042","volume":"4","author":"P Sagulenko","year":"2018","unstructured":"Sagulenko, P., Puller, V. & Neher, R. A. TreeTime: maximum-likelihood phylodynamic analysis. Virus Evol. 4, vex042 (2018).","journal-title":"Virus Evol."},{"key":"43703_CR52","doi-asserted-by":"publisher","first-page":"e0260884","DOI":"10.1371\/journal.pone.0260884","volume":"16","author":"F Gentilini","year":"2021","unstructured":"Gentilini, F. et al. Modelling RT-qPCR cycle-threshold using digital PCR data for implementing SARS-CoV-2 viral load studies. PLoS ONE 16, e0260884 (2021).","journal-title":"PLoS ONE"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43703-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43703-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43703-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T08:28:19Z","timestamp":1701851299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43703-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43703"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-43703-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.09.08.23295250","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"8 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.A.N. consults for Moderna on influenza virus evolution. A.v.G. and N.W. received grant funding from Sanofi. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8078"}}